Top Big Data Companies With Best Stability & Growth (2,229)

Strong Revenue Growth: Revenue is accelerating, with FY2025 up 19% and Q1 2026 up 22%, and guidance of $92–$94M implies about 20–22% further growth in 2026. Record analysis volumes and rising net dollar retention support the trajectory.

Strategic Partnerships: High-profile collaborations with Memorial Sloan Kettering (MSK‑ACCESS and MSK‑IMPACT), AstraZeneca, MD Anderson, and large U.S. health systems expand access and credibility for new applications. These relationships are highlighted as drivers of continued double-digit growth through 2026.

Market Expansion: The company is adding customers and scaling usage globally—reaching 537 core genomics customers and a record 108,000 analyses in Q1 2026—with particularly strong momentum in the U.S. and APAC. Reaffirmed U.S. expansion and new application launches are expected to sustain this momentum.

Strong Revenue Growth: Revenue is reported at $46.1 billion for 2025, up 6.9% year over year, placing the company at No. 100 on the 2026 Fortune 500. These figures indicate expanding scale on a consolidated basis.

Investor Backing & Capital Strength: Total adjusted capital rose to $34.4 billion at year‑end 2025 with all major ratings affirmed, and AM Best assigned “aa-” to a new $1.0 billion surplus‑note issuance. A record estimated $2.9 billion policyowner dividend for 2026 reinforces retained strength for a mutual insurer.

Diversified Revenue Streams: The business spans whole life, annuities, institutional solutions, and asset management via Barings, with additional contributions from Rothesay. Disclosures describe broad‑based sales and earnings across these engines, helping smooth cyclicality.

Strong Revenue Growth: Clearing-fee revenue is reported at $712.9M in 2025, up about 49% from 2024, supported by record contract volumes. Mid-2026 data shows options activity up 45% year over year in June with year-to-date ADV up about 24%, reinforcing the expansion.

Strong Market Position & Advantage: Being the sole clearer of U.S.-listed options places the organization at the center of record market activity, with about 15.26B total contracts cleared in 2025. Large risk resources—$393B of margin and a $21.9B clearing fund—underscore scale and capacity.

Market Expansion: Services expanded in May 2026 to include MIAX Futures, bringing coverage to 21 exchanges and trading platforms. ETF and index options strength alongside the added venue broadens the footprint.

Investor Backing & Capital Strength: Investor backing is described as robust, including $125M in financing from Vista Credit Partners (2023) and a majority stake by Nordic Capital (2025) to fund product, hiring, and partnerships. These moves are presented as enabling continued expansion and R&D.

Innovation-Driven Growth: Product momentum is evident through a next‑generation lakehouse data platform launched in February 2024 and subsequent AI‑enabled solutions for interoperability, network modeling, and precision medicine (2024–2026). CareJourney‑infused capabilities and an active platform roadmap signal an innovation‑led path to growth.

Market Expansion: Market reach appears to be widening, with more than 2.25 million additional value‑based lives, an ecosystem exceeding 170 million clinical patient records, and hundreds of provider, payer, government, and life sciences customers cited. Entry into life sciences via data marketplace listings further broadens addressable demand.

Strong Revenue Growth: Net revenue increased in fiscal 2025 and continued to rise in early 2026, with management characterizing the start of the year as solid and reaffirming the full‑year outlook. This points to ongoing top‑line momentum despite a normalizing environment.

Strong Market Position & Advantage: The company reports a clear global leadership position in biscuits and a top‑tier position in chocolate, underpinned by iconic brands across many countries. Such scale and category strength support steady demand and pricing resilience through input‑cost volatility.

Future-Ready Strategy: Management reiterates a long‑term growth algorithm for organic revenue and EPS and has sharpened focus on core snacks through portfolio actions like the gum divestiture. This signals a durable strategic frame aimed at resilient, sustainable expansion beyond near‑term swings.

Strong Revenue Growth: Revenue grew strongly year over year to $687.6M in Q1 FY2027 on top of a larger FY2026 base, and management’s FY2027 outlook points to continued growth for the full year.

Healthy Cash Flow: Free cash flow increased materially to $197.5M in Q1 FY2027 versus the prior year, with improving non‑GAAP profitability and positive GAAP net income in recent quarters.

Customer Loyalty & Retention: Expansion within existing accounts is reflected in the rising cohort of $100K+ ARR customers (2,895) and a sharp increase in remaining performance obligations to $1.46B, signaling durable demand.

Strategic Partnerships: Partnerships with major clouds are emphasized through joining Google Cloud Partner Advantage as a Build partner and listing Screen on both Google Cloud and AWS Marketplaces, positioning the company to co‑sell and expand distribution. These channels typically lower procurement friction and surface the offering to existing cloud customers.

Product Line Growth: Product breadth spans Crunch (data reduction), Screen (privacy/safety), Chronicle (data visibility), and a recent launch of Myelin for agent infrastructure, with active docs and blogs signaling ongoing development. This cadence indicates a platform expanding beyond its initial offering into adjacent capabilities.

Investor Backing & Capital Strength: A sizable Series A round in June 2023 led by NEA and Bain Capital Ventures is cited as providing capital to scale product and sales. The funding and named backers support the company’s ability to execute on its roadmap.

Investor Backing & Capital Strength: Capital raised is described as substantial, with a $372M Series D in June 2024 led by a16z and participation from Sanofi, explicitly earmarked to grow the pipeline and AI platform. References to $600M+ in total funding and ongoing hiring point to a reinforced capital base supporting expansion.

Strategic Partnerships: Collaborations with Sanofi and OpenAI are presented as first-in-class efforts to apply AI across drug development, signaling external validation and increased resourcing. A 2025 Sanofi licensing deal worth up to €545M further indicates the capability to progress and transact assets with blue‑chip partners.

Product Line Growth: Pipeline activity is shown to be broadening via in‑licensing (e.g., a CNS‑penetrant TYK2 inhibitor in Dec 2025) and movement into the clinic, including first‑in‑human dosing on June 9, 2026. Together, these moves suggest more programs are entering and advancing through clinical stages.

Strong Revenue Growth: The company stated it tripled revenue in 2024 and achieved roughly 10x growth over two years, with profitability described as "on the horizon." These gains are presented alongside a pivot to an enterprise software-and-services model.

Investor Backing & Capital Strength: Closed a $120 million oversubscribed Series D on May 13, 2025, co-led by Goldman Sachs and Smith Point Capital, with an additional credit facility noted by independent local coverage. This late-stage capital is framed to fund product development and platform expansion.

Strategic Partnerships: Large carriers are adopting the platform, exemplified by Transamerica’s 2025 FFIUL II Express with 100% instant-decision underwriting. Partnerships highlighted include Nationwide, USAA, and Sammons, with company materials citing rapid product delivery and scaled service operations.

Innovation-Driven Growth: Multiple AI-first launches — including the Intelligent Control Tower (January 2025) and an agentic ocean booking platform (May 2026), with continued AI feature rollouts into 2026 — point to sustained product velocity beyond core visibility. This cadence signals ongoing investment in automation and orchestration capabilities.

Strategic Partnerships: Alliances with FedEx and Chorus, along with an APAC push supported by Mitsui/MKI, expand data access, distribution, and regional reach. Regular product and customer updates through the press channel indicate continued ecosystem momentum.

Strong Market Position & Advantage: Leader placement in Gartner’s 2024 RTTVP Magic Quadrant and marketing claims of processing roughly 3.2 million shipments per day across 200+ countries underscore significant network scale. Multimodal coverage and visible category presence suggest durable competitive positioning.

Innovation-Driven Growth: Regulatory milestones include FDA 510(k) clearance for the eVO2peak Module alongside multiple FDA‑cleared algorithms, signaling validated advancements in the product suite. AI analytics and quality certifications (ISO 13485/MDSAP) are positioned to support wider clinical and commercial deployment.

Investor Backing & Capital Strength: The March 2025 acquisition by Kardigan is presented as integrating Prolaio into a larger heart‑health platform that expands resources, customers, and reach. Being a Kardigan subsidiary with platform‑level integration into cardiovascular trials indicates ongoing backing for scale.

Market Expansion: Operations are cited across 20+ countries with indications of further expansion, reflecting a widening footprint and maturing deployment. The combined Prolaio–Kardigan platform is positioned to reach more patients, researchers, and biopharma partners globally.

Strong Revenue Growth: Revenue is described as having surged in 2020 and 2021 and continued to rise into 2024, indicating a consistent upward trajectory since launch. Recent estimates and ongoing customer additions support continued scaling into 2025–2026.

Investor Backing & Capital Strength: The company has secured substantial funding totaling about $114.5M, including a major Series C in 2022 led by Accel, Insight Partners, and Tiger Global. This capital base has underpinned multi‑year product and go‑to‑market expansion without frequent new rounds.

Innovation-Driven Growth: Product momentum includes AI-focused releases such as the AI Impact Dashboard (2024) and a smarter Jellyfish Assistant (March 2026), alongside availability on AWS Marketplace. These launches and partnerships position the company to capture demand around measuring and improving AI-driven engineering.

Profitability: Operations are described as bootstrapped and profitable with zero outside capital, with $20M+ ARR (recently cited at $22M) and high margins. This profile points to a self-funded business capable of sustaining growth investments.

Strong Hiring & Retention: Multiple senior openings posted in June–July 2026 (AI/ML engineers, revenue systems, Chief of Staff, Head of Commercial, Product) on both the company site and LinkedIn indicate active headcount expansion. The role mix suggests scaling across product, engineering, and go-to-market.

Innovation-Driven Growth: A March 2026 rebrand to Product.ai, launch of a “truth layer for commerce,” and fresh research plus public programming signal ongoing product building and go-to-market momentum. These moves reflect an emphasis on new capabilities and category creation.

Investor Backing & Capital Strength: Investor backing is underscored by a $100 million minority investment from Blackstone Growth in January 2026, described as a Series C with a notable valuation step-up. Feedback suggests this top-tier funding signals confidence and provides resources to scale.

Strong Hiring & Retention: Hiring momentum is evident with headcount rising from about 308 in 2024 to roughly 399 by December 2025 and ongoing recruiting into 2026. Feedback suggests multiple job postings and “growing quickly” language point to continued team expansion.

Strong Revenue Growth: Revenue trajectory is portrayed as rapid, with company materials claiming 10x growth over four years (not independently audited). Feedback suggests this aligns with the scaling narrative tied to recent funding and hiring.

Profitability: Optum generated $4.0B in operating earnings in Q2 2026 with about 160 bps year‑over‑year margin expansion, and the parent raised its 2026 adjusted EPS outlook. Operating earnings also improved at Optum Insight and Optum Rx, signaling firming margin and earnings momentum.

Cost & Operational Efficiency: Operational improvements at Optum Insight and Optum Rx’s shift toward more transparent, fee‑based pricing supported better segment profitability. Margin expansion at the Optum level despite pockets of revenue softness indicates execution on efficiency initiatives.

Innovation-Driven Growth: Optum Insight introduced new AI‑enabled offerings, and Optum closed the Alegeus acquisition to expand consumer‑directed benefits capabilities. Model changes at Optum Rx toward transparent pricing further reflect product and business model innovation.

Investor Backing & Capital Strength: A majority investment from Vista Equity Partners at approximately $3 billion (Oct 2025), followed by a $750 million private credit financing in March 2026, signals substantial external support and resources for scaling. Materials from a prior lead investor also reference ARR more than tripling since 2021 and the business scaling to profitability, reinforcing perceived financial durability.

Strong Market Position & Advantage: Consecutive Leader placements in Gartner’s Magic Quadrant for Digital Employee Experience Management Tools through 2026 (reported as a third straight year) and a 2024 Forrester Wave Leader position indicate competitive strength in a still‑maturing category. This sustained analyst recognition underscores durable positioning with large enterprises.

Innovation-Driven Growth: Since launching the Infinity platform in 2022, the company added AI Drive (Sept 2025) and Spark (Jan 2026), a personal IT agent, consistent with an expanding, AI‑forward platform strategy. The January 2024 acquisition of AppLearn further broadened capabilities into digital adoption.

Strong Revenue Growth: Revenue is described as rising from $58 million in 2023 to $79 million in 2024 and $101 million in 2025, with an annualized run rate crossing $130 million by early 2026. This trajectory reflects renewed momentum after earlier stagnation.

Profitability: The company achieved its first annual profit in 2025, signaling improved financial stability and discipline. Subsequent reporting still places the business at a nine‑figure run rate.

Market Expansion: The Possible Loan rolled out to 19 new states in 2025, bringing operations to roughly 33 states and increasing reach to underserved communities. Ongoing rollouts and partnerships are cited as supporting broader distribution.

Strong Revenue Growth: Annual recurring revenue is reported to have grown 12% year over year in 2023, with higher‑margin recurring services up 43%. These disclosures indicate an expanding subscription mix and momentum exiting 2023.

Innovation-Driven Growth: New AI capabilities were launched with Vendavo AI in September 2025 and further enhanced in Spring 2026 (e.g., AI Pricing Assistant and an ML‑driven price rules generator). This cadence shows active platform investment that broadens use cases across pricing, quoting, and rebates.

Strong Market Position & Advantage: The company was named a Leader in the April 2026 Gartner Magic Quadrant for B2B Pricing & Rebate Optimization Software. This recognition signals competitive strength and momentum in its core category.

Profitability: Recent results show a return to GAAP profit and faster growth in adjusted EBITDA, with management lifting full‑year margin targets. This points to operating leverage as the business mix shifts toward higher‑margin CTV.

Strong Market Position & Advantage: Industry evaluations and benchmarking cite leadership among independent SSPs, particularly in CTV, and recent quarters show that segment expanding as a share of the business. This positioning supports continued momentum as premium streaming relationships deepen.

Healthy Cash Flow: Management raised its outlook for free cash flow while keeping capital spending steady, indicating confidence in cash generation and investment capacity. Improving EBITDA guidance further strengthens the view of solid cash conversion.

Strong Revenue Growth: Revenue is rising at a mid‑ to high‑single‑digit pace for full‑year 2025 and accelerated in early 2026, with organic gains supported by core franchises. Growth is led by Morningstar Credit alongside steady contributions from PitchBook and the Morningstar Direct Platform.

Profitability: Operating results show clear momentum into 2026, with strong year‑over‑year increases in operating income and per‑share earnings indicating operating leverage. Margin expansion reflects mix benefits and disciplined execution.

Diversified Revenue Streams: Multiple engines—Morningstar Credit, PitchBook, the Morningstar Direct Platform, and Morningstar Retirement—are contributing to growth rather than a single product or geography. This breadth supports durability even as individual segments cycle.